SCHEMBL4073807

SCHEMBL4073807

Cc1ccc2[nH]c(=O)c(CN([C@H]3CCC[C@@H]3O)S(=O)(=O)c3ccc4c(c3)OCCN4C)cc2c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 13/20 0.48
ALDH1A1 P00352 11/20 0.48
MAPT P10636 2/20 0.48
RXFP1 Q9HBX9 2/20 0.44
HPGD P15428 6/20 0.44
GAA P10253 2/20 0.44
HSD17B10 Q99714 8/20 0.43
KMT2A Q03164 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
MEN1 O00255 1/20 0.43
USP2 O75604 3/20 0.41
MAPK1 P28482 2/20 0.40
HTT P42858 2/20 0.40
TSHR P16473 1/20 0.40
ALOX12 P18054 1/20 0.40
ESR1 P03372 1/20 0.40
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4073815 1.00 KDM4E (0.48) KDM4EALDH1A1MAPTRXFP1HPGD
SCHEMBL4073811 1.00 KDM4E (0.48) KDM4EALDH1A1MAPTRXFP1HPGD
SCHEMBL4069803 0.94 KDM4E (0.44) KDM4EALDH1A1MAPTRXFP1HPGD
SCHEMBL4069801 0.94 KDM4E (0.44) KDM4EALDH1A1MAPTRXFP1HPGD
SCHEMBL4069807 0.94 KDM4E (0.44) KDM4EALDH1A1MAPTRXFP1HPGD
SCHEMBL4074657 0.86 ALDH1A1 (0.47) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL4074658 0.86 ALDH1A1 (0.47) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL4074655 0.86 ALDH1A1 (0.47) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL4075786 0.86 HSD17B10 (0.53) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL4079618 0.86 HSD17B10 (0.53) KDM4EALDH1A1MAPTHPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP claimed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US claimed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO claimed
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP disclosed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US disclosed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof ABCG2, ATP5ME, ATP5MG KDM4E 2403/4885ALDH1A1 1055/4885MAPT 4297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.